US Probes Merck's Marketing Of 3 Drugs

Law360, New York (August 8, 2011, 8:41 PM EDT) -- Merck & Co. Inc. disclosed Monday that the U.S. Department of Justice had asked it to turn over documents detailing marketing practices for cancer drugs Temodar and Intron A and hepatitis C drug PegIntron as part of a criminal investigation.

In a quarterly filing with the U.S. Securities and Exchange Commission, the Whitehouse Station, N.J.-based company said the DOJ issued a subpoena seeking information on marketing and selling activities related to the three drugs from January 2004 to the present.

"We're cooperating with the government," Merck...
To view the full article, register now.